Next generation drug conjugates for cancer treatment

Informations projet

Syndivia

N° de convention de subvention: 735764

DOI

10.3030/735764

Projet clôturé

Date de signature de la CE 24 Juillet 2016

Date de début 1 Juillet 2016

Date de fin 30 Novembre 2016

Financé au titre de

• SOCIETAL CHALLENGES - Health, demographic change and well-being

Coût total

€ 71 429,00

Contribution de l’UE

€ 50 000,00

Coordonné par

SYNDIVIA
France

Periodic Reporting for period 1 - Syndivia (Next generation drug conjugates for cancer treatment)

Période du rapport: 2016-07-01 au 2016-11-30

Résumé du contexte et des objectifs généraux du projet

Pancreatic cancer has the lowest survival rate of all cancers and is the fourth leading cause of death by cancer in Europe. Syndivia has developed SDV1001, a small molecule prodrug customised to target the pancreatic tumour microenvironment upon conjugation with serum albumin found in blood. The formulation offers a specialist target therapy for treating cancer without harming healthy cells surrounding the tumour. The objectives of the innovation project are to advance the drug through preclinical toxicology studies and commence Phase I/IIa clinical trials with cancer patients.

Travail effectué depuis le début du projet jusqu’à la fin de la période considérée dans le rapport et principaux résultats atteints jusqu’à présent

Syndivia undertook a full analysis of the both the technical and business potential of the SDV1001 prodrug. Syndivia analysed results of early preclinical trials and the efficacy of the product was proven through the treatment of mice. The response to SDV1001 displayed 92-100% tumour regression and no noticeable side effects. Syndivia also evaluated the strategy for out-licensing later development and performed detailed projections for the company growth. Syndivia also outreached many potential customers and stakeholders building a strong base in the oncology and pharma networks.

Progrès au-delà de l’état des connaissances et impact potentiel prévu (y compris l’impact socio-économique et les conséquences sociétales plus larges du projet jusqu’à présent)

The expected outcome of the project is to gain first results from clinical trials and advance toward the out-licensing of the prodrug. If clinical trials are successful, the SDV1001 will be a highly valuable investment for pharmaceutical companies. The SDV1001 development will boost economic growth and create jobs within Syndivia and on a wider scale with CMOs and CROs in Europe.

biomolecule-conjugation.png